Research Services, Programs & Laboratories
The Department of Pathology is committed to upholding the tradition of research excellence known at the VCU Medical Center. The driving force behind everything we do is simply to provide patients with the best medical care possible.
We are also dedicated to facilitating the research of other faculty in the institution or the community who require use of our state-of-the-art equipment, staff and/or faculty.
Clinical Pathology Research Services (CPRS)
The Division of Clinical Pathology offers a diverse menu of laboratory testing services. Our laboratories are well equipped to provide the highest level of support to health care providers and researchers through leading-edge technologies, quality assurance measurements, and laboratory management programs.Clinical Laboratory Testing Research Specimen Processing
Tissue and Data Acquisition and Analysis Core
TDAAC is a resource designed to provide high quality controlled human tissue samples to VCU investigators as well as provide customized services to assist them in all tissue collection, consenting, and processing needs.Find out more about TDAAC
The Molecular Pathology Research Services (MPRS) specializes in providing Next Generation Sequencing (NGS) services in a CLIA’88 certified laboratory for research, translational research, and clinical trials.
The Molecular Diagnostics Clinical Trial Services specializes in providing nucleic acid based testing for clinical studies of new in-vitro diagnostics tests as well as clinical trials that required molecular diagnostics and pharmacogenetic testing.Molecular Pathology Research Services (MPRS) Molecular Diagnostics Clinical Trial Services
Research In Progress
Join us for our 2018-2019 Research In Progress Series:
Location: Sanger Hall, Room 4-024
Date/Time: Wednesdays, 12pm-1pm
Second Wednesday of the Month
Pathology Research Laboratories:
Our research and administration space (23,000 nsf) recently undergone a state-of-the-art renovation. Currently, our department has 10 principal investigators involved in basic/translational research.
Atfi Lab - Molecular mechanisms of cancer and cancer-associated cachexia
Bos Lab - Tumor promoting mechanisms by regulatory T (Treg) cells
Clevenger Lab - Role of the prolactin receptor signaling in breast cancer pathogenesis
Gerszten Lab - Paleopathology
Harrell Lab - Identification of genetic mediators of breast cancer liver metastasis, METAvivor
Jackson-Cook Lab - Genetic/Epigenetic factors contributing to chromosomal instability
Koblinski Lab - Role of syndecans in breast cancer metastasis to the brain
Oh Lab - IGFBP-3/IGFBP-3R axis in human cancer and the pathophysiology of the IGFBP-related proteins
Radhakrishnan Lab - Understanding and targeting protein degradation pathways in cancer
Sirica Lab - Altered Growth Factor Pathways in Biliary Cancer
- Non-alcoholic Steatohepatitis, NIH, Melissa Contos, MD, VCUHS site Pathologist
- Molecular mechanisms underlying recruitment of multipotent stromal cells to the breast tumor microenviroment, Michael O. Idowu, MD, MPH
- Lysophosphatidic Acid in Oncogenesis, NIH, Michael O. Idowu, MD, MPH (Co-investigator)
- Phase II Study of 3’Deoxy-3’-18F Fluorothymidine (FLT) in Invasive Breast Cancer, NCI/ACRIN, Michael O. Idowu, MD, MPH (Co-investigator)
- Standardization of urine albumin testing by clinical laboratories, NKDEP/NIDDK, Greg Miller, PhD and Lorin Bachmann, PhD (Principal Investigator)
- Commutable reference materials for clinical laboratory calibration traceability, Greg Miller, PhD
- Harmonization assessment of serum albumin methods, Industry Sponsored, Greg Miller, PhD and Lorin Bachmann, PhD (Principal Investigator)
- Evaluation of analytical performance characteristics of 25-OH Vitamin D methods, Industry Sponsored, Lorin Bachmann, PhD (Principal Investigator)
Cancer Genomics and Development of Diagnostic Tools & Therapies, Andrea Ferreira-Gonzalez, PhD
The faculty members in Transfusion Medicine are engaged in several major research projects. The “Age of Blood in Children in Pediatric Intensive Care Units (ABC-PICU)” study is a large, multi-center, randomized, double-blinded control trial aimed at determining if red blood cells stored for seven or fewer days will result in improved clinical outcomes in critically ill children when compared blood issued according to standard practices, which may include blood older than seven days. In another multi-center study, we are participating in an Investigational New Drug Application (IND) for “Pre-Hospital Use of Plasma for Traumatic Hemorrhage (PUPTH)”. This study involves the administration of thawed type A plasma in the pre-hospital setting for victims of poly trauma with major hemorrhage with the objectives of demonstrating that thawed plasma can be administered safely in this setting, and that such administration can improve outcomes. In addition, the apheresis unit contributed data to the NHLBI ReSTART trial, looking at the role of rituximab in the treatment of TTP. The faculty and staff in Transfusion Medicine are also involved in developing new clinical applications for cutting edge technology such as the use of DNA-based testing (genotyping) of red blood cell antigen genes to deduce detailed antigen profiles for patients that present difficult transfusion problems, such as patients who have received multiple or recent transfusions.